Coronavirus / COVID

New research presented at ERS shows how critically ill COVID-19 patients face cardiac and pulmonary burdens weeks after recovery.

A Rapid Response in BMJ argues that to achieve Zero-COVID, we need to broaden our thinking to include the controlled and careful acquisition of population immunity.

In this segment, Dysphagia expert Rinki Varindani Desai shares her perspective on the need for an adaptive health care system response that incorporates equity across health burdens.

How a Chicago-based surgeon managed an unprecedented procedure for young woman at the height of the pandemic.

An examination of a patient presenting with the condition in the early days of the pandemic without the access to current care protocols.

SARS-CoV-2 is unlikely to pass through the breast milk of infected mothers to their infants, according to a recent evaluation of breast milk samples from 18 women who tested positive for the COVID-19.

A new report shows a UK-based participant experienced a serious adverse event, but is anticipated to recover.

A total of 9 firms signed the letter promising to put safety at the top of the priority list in ongoing COVID-19 vaccine development projects.

A follow-up on analysis from earlier in the pandemic reveals that virulence in children remained stable over a 5-month period.

The story of an early-infected US physician who launched a non-profit, participated in trials, and guided her peers after overcoming infection.

An observational study in the United Kingdom supports the concepts of a hyperinflammation phenotype for severe COVID-19 cases and could help guide risk assessment, precision medicine, and trial design.

A new study sought to quantify the impacts of various testing strategies. It found rapid testing and self-isolation were the most critical factors.

The phase 1/2 findings show the recently regulated two-dose vaccine was associated with no serious adverse events and antibody response within 21 days.

At a time when schools and college campuses have reopened, an expert discusses adolescents' trends in spreading COVID-19 more easily, and the lack of testing available to them.

This test simultaneously detects and differentiates between SARS-CoV-2, influenza A and B.

Frontline health care workers had a nearly 12 times higher risk of testing positive for COVID-19 compared with individuals in the general community.

JAMA Internal Medicine study focused on patients with mild disease.

A review of the week's top infectious disease news, including links established between mental health and pursuit of need medical care during COVID-19.

How children and adolescents contract, spread, and suffer through the virus differently than other age groups.

New study suggests a connection between widespread mental health challenges and the decline in care during COVID-19.

If phase 1/2 data is positive, the companies plan to move into phase 3 by December.

Odds of better clinical status were higher for patients with moderate COVID-19 who received a 5-day course of remdesivir than for those receiving standard care, according to the most recent randomized clinical trial of the antiviral drug.

Rinki Varindani Desai shares some of the challenges COVID-19 patients with lung injury have faced with Medicare after leaving the hospital.

The federal agency sent a checklist and priority list to all 50 states and 5 large American cities as it prepares for vaccine approval.

Dysphagia specialist Rinki Varindani Desai shares her perspective on how COVID-19 has impacted her work and patients.

A team at UCSF has created a model which estimates how many pediatric cases are going unnoticed in any US county at any time.

A trio of studies appearing in JAMA today now support steroid use to reduce mortality in patients with severe SARS-CoV-2 infections.

The test designed to detect SARS-CoV-2 will be available in Europe later this month and provides results in 15 minutes.

Heat Biologics CEO Jeff Wolf talks with Contagion about the firm's effort to develop a vaccine for the coronavirus which can potentially be administered for some seniors by taking advantage of prior immune mechanisms.

One effort to develop a SARS-CoV-2 vaccine focuses on combining antibody and T cell immunity, using a gp96 protein based technology.